SCHEMBL732895

SCHEMBL732895

CCOc1cc(C(=O)O)cc(-c2nnn[nH]2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.51
BRD2 P25440 3/20 0.51
CREBBP Q92793 3/20 0.51
ALPL P05186 1/20 0.43
RXRA P19793 1/20 0.43
RXRB P28702 1/20 0.43
PLA2G2A P14555 1/20 0.40
MAPT P10636 2/20 0.39
GAA P10253 1/20 0.39
FABP1 P07148 2/20 0.39
PLA2G4B P0C869 1/20 0.38
TP53 P04637 1/20 0.36
PKM P14618 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
PTGS2 P35354 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL731048 0.87 BRD4 (0.43) BRD4BRD2CREBBPALPLMAPT
SCHEMBL2513559 0.81 ALOX15 (0.36) MAPTTP53SMN1; SMN2TDP1NPC1
SCHEMBL3655711 0.80 PTGER1 (0.44) CREBBPRXRARXRBMAPTTP53
SCHEMBL3650536 0.75 ALPL (0.48) ALPLRXRAMAPTGAASMN1; SMN2
SCHEMBL2655120 0.74 PLA2G2A (0.65) BRD4BRD2CREBBPRXRARXRB
SCHEMBL3184334 0.74 PLA2G2A (0.59) BRD4BRD2CREBBPRXRARXRB
SCHEMBL3656495 0.74 MAP4K4 (0.42) RXRAPKMTDP1
SCHEMBL730918 0.74 LMNA (0.50) SMN1; SMN2MRGPRX4NR1H4NPC1RAB9A
SCHEMBL3650391 0.73 TRPA1 (0.39) SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL732864 0.73 ALDH1A1 (0.35) ALPLMAPTGAATP53NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 BRD4 67/4885BRD2 953/4885CREBBP 3128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.